ソマトスタチン類似体の世界市場レポート 2025年

ソマトスタチン類似体市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.2％で94億8,000万米ドルに成長します。予測期間の成長は、正味罹患率の継続的な上昇、希少疾患への研究フォーカス、併用療法の開発、個別化医療の進歩、がん医療における世界ヘルスへの取り組みに起因すると考えられます。予測期間における世界の主な動向としては、世界の高齢化、新興国市場におけるヘルスケアインフラの開拓、戦略的提携とパートナーシップ、価格圧力と償還の課題、ヘルスケアにおける技術統合などが挙げられます。

ソマトスタチン類似体市場は、神経内分泌腫瘍の発生率の増加により大きな成長が見込まれています。神経内分泌腫瘍は特殊な神経内分泌細胞から発生し、過剰なホルモン産生を引き起こす可能性があります。ソマトスタチン類似体は、ホルモンレベルの調節、腫瘍の成長抑制、カルチノイド疾患に伴う症状の緩和において重要な役割を果たします。例えば、2022年にCancer Australiaは、オーストラリアにおける神経内分泌腫瘍の新規症例約5,437例を報告し、この疾患の有病率を浮き彫りにしました。神経内分泌腫瘍の罹患率の上昇は、ソマトスタチン類似体市場の拡大を促進する重要な要因です。

ソマトスタチン類似体市場の成長は、高齢化人口の増加によって推進されると予想されます。65歳以上の高齢者の割合が高くなる人口動態の変化は、ソマトスタチン類似体の使用を必要とする疾患の発生率の上昇に関連しています。Visual Capitalistが報告しているように、2022年現在、65歳以上の高齢者は世界で7億7,100万人おり、世界人口の10％近くを占めています。この人口動向は、ソマトスタチン類似体を含む医薬品の需要拡大に寄与しています。その結果、高齢化人口の拡大がソマトスタチン類似体市場成長の重要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ソマトスタチン類似体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のソマトスタチン類似体市場：成長率分析
• 世界のソマトスタチン類似体市場の実績：規模と成長, 2019-2024
• 世界のソマトスタチン類似体市場の予測：規模と成長, 2024-2029, 2034F
• 世界ソマトスタチン類似体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のソマトスタチン類似体市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オクトレオチド
• ランレオチド
• パシレオティド
• 世界のソマトスタチン類似体市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 先端巨大症
• クッシング症候群
• 神経内分泌腫瘍
• カルチノイド症候群
• その他の治療法
• 世界のソマトスタチン類似体市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 製薬会社
• 世界のソマトスタチン類似体市場、オクトレオチドの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 持続放出型（LAR）製剤
• 短時間作用型製剤
• 世界のソマトスタチン類似体市場ランレオチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デポ製剤
• 注射剤
• 世界のソマトスタチン類似体市場パシレオチドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 長時間作用型注射剤
• 皮下製剤

第7章 地域別・国別分析

• 世界のソマトスタチン類似体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のソマトスタチン類似体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ソマトスタチン類似体市場：競合情勢
• ソマトスタチン類似体市場：企業プロファイル
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • Midatech Pharma plc Overview, Products and Services, Strategy and Financial Analysis
  • Crinetics Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Peptron Inc.
• Teva Pharmaceutical Industries Ltd.
• Camurus AB
• Bayer Aktiengesellschaft
• Cadila Healthcare Limited
• Amneal Pharmaceuticals Inc.
• Recordati S.p.A.
• Amryt Pharma plc
• Ipsen Pharma SA
• Fresenius Kabi AG
• Chiasma Inc.
• Merck KGaA
• Sanofi S.A.
• Sandoz International GmbH
• Takeda Pharmaceutical Company Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ソマトスタチン類似体市場2029：新たな機会を提供する国
• ソマトスタチン類似体市場2029：新たな機会を提供するセグメント
• ソマトスタチン類似体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A somatostatin analog is a man-made version of somatostatin, a natural hormone that regulates the production of various hormones in the body, such as serotonin and growth hormone. The primary purpose of somatostatin analogs is to slow down the release of these hormones. These analogs are particularly employed to alleviate symptoms associated with carcinoid syndrome, which may include diarrhea and skin flushing.

The key somatostatin analogs in medical use are octreotide, lanreotide, and pasireotide. Octreotide is a medication designed to mimic the effects of somatostatin by blocking the release of growth hormones. It is commonly utilized in the treatment of specific conditions such as tumor-related diarrhea and flushing. These somatostatin analogs find applications in addressing various medical conditions, including acromegaly, Cushing's syndrome, neuroendocrine tumors, carcinoid syndrome, and others. The end users for these analogs include hospitals and pharmaceutical companies, emphasizing their significance in medical treatments and therapies.

The somatostatin analogs market research report is one of a series of new reports from The Business Research Company that provides somatostatin analogs market statistics, including the somatostatin analogs industry global market size, regional shares, competitors with a somatostatin analogs market share, detailed somatostatin analogs market segments, market trends, and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. This somatostatin analogs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The somatostatin analogs market size has grown strongly in recent years. It will grow from$6.73 billion in 2024 to $7.18 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $9.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare.

The somatostatin analogs market is expected to experience significant growth due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, originating in specialized neuroendocrine cells, can lead to excessive hormone production. Somatostatin analogs play a crucial role in regulating hormone levels, inhibiting tumor growth, and alleviating symptoms associated with carcinoid disease. For instance, in 2022, Cancer Australia reported approximately 5,437 new cases of neuroendocrine tumors in Australia, highlighting the prevalence of this condition. The rise in neuroendocrine tumor incidence is a key factor driving the expansion of the somatostatin analogs market.

The growth of the somatostatin analogs market is expected to be propelled by the increasing aging population. The demographic shift toward a higher proportion of individuals aged 65 and older is associated with a higher incidence of diseases that necessitate the use of somatostatin analogs. As of 2022, there were 771 million people aged 65 and above globally, constituting nearly 10% of the world's population, as reported by Visual Capitalist. This demographic trend contributes to a growing demand for pharmaceuticals, including somatostatin analogs, as they are commonly used in conditions prevalent among the elderly. Consequently, the expanding aging population is a significant driver for the growth of the somatostatin analogs market.

Major companies in the somatostatin analogs market are focused on developing advanced products, such as targeted radiopharmaceuticals, to improve the precision and effectiveness of cancer treatments, particularly for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized drugs that combine radiation-emitting isotopes with molecules designed to specifically bind to cancer cells, enabling precise delivery of therapeutic radiation to tumor sites while reducing exposure to surrounding healthy tissues. For example, in January 2024, Lantheus, a US-based company specializing in radiopharmaceuticals, launched Lutetium Lu-177 Dotatate. This radiolabeled somatostatin analog is used in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have shown that it significantly improves progression-free survival and response rates compared to traditional somatostatin analogs like octreotide, making it a crucial option for patients whose disease has progressed despite previous treatments. Its targeted approach allows for effective tumor control while minimizing systemic exposure, enhancing the overall therapeutic profile for managing neuroendocrine malignancies.

Major companies in the somatostatin analogs market are concentrating on developing advanced products, such as oral selective agonists, to enhance patient compliance and improve the treatment of conditions linked to excess growth hormone, like acromegaly. Oral selective agonists are compounds designed to selectively activate specific receptors in the body when taken orally, resulting in targeted biological responses while minimizing effects on other receptor types. For instance, in September 2024, Crinetics Pharmaceuticals Inc., a US-based company focused on discovering and developing novel therapeutics for rare endocrine diseases and endocrine-related tumors, submitted a new drug application for paltusotine to treat acromegaly. Paltusotine is an oral, nonpeptide small-molecule agonist specifically targeting somatostatin receptor type 2 (SST2). This innovative drug offers a once-daily dosing regimen, improving patient compliance compared to traditional injectable somatostatin analogs like octreotide and lanreotide. Clinical studies have demonstrated that paltusotine effectively lowers insulin-like growth factor I (IGF-I) levels, presenting a promising alternative for patients needing long-term management of hormone hypersecretion.

In October 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, partnered with Philogen S.p.A. to enhance its portfolio and broaden access to innovative cancer treatments. This collaboration aims to commercialize the under-development skin cancer drug Nidlegy in Europe, Australia, and New Zealand. Philogen S.p.A. is an Italy-based biotechnology company dedicated to developing targeted therapeutics for oncology.

Major companies operating in the somatostatin analogs market include Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH

North America was the largest region in the global somatostatin analogs treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the somatostatin analogs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Somatostatin Analogs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on somatostatin analogs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for somatostatin analogs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The somatostatin analogs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Octreotide; Lanreotide; Pasireotide
• 2) By Treatment: Acromegaly; Cushing's Syndrome; Neuroendocrine Tumors; Carcinoid Syndrome; Other Treatments
• 3) By End User: Hospital; Pharmaceutical Companies
• Subsegments:
• 1) By Octreotide: Long-Acting Release (LAR) Formulations; Short-Acting Formulations
• 2) By Lanreotide: Depot Formulations; Injectable Formulations
• 3) By Pasireotide: Long-Acting Injectable Formulations; Subcutaneous Formulations
• Companies Mentioned: Novartis International AG; Pfizer Inc.; Sun Pharmaceutical Industries Limited; Midatech Pharma plc; Crinetics Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Somatostatin Analogs Market Characteristics

3. Somatostatin Analogs Market Trends And Strategies

4. Somatostatin Analogs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Somatostatin Analogs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Somatostatin Analogs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Somatostatin Analogs Market Growth Rate Analysis
• 5.4. Global Somatostatin Analogs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Somatostatin Analogs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Somatostatin Analogs Total Addressable Market (TAM)

6. Somatostatin Analogs Market Segmentation

• 6.1. Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Octreotide
• Lanreotide
• Pasireotide
• 6.2. Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acromegaly
• Cushing's Syndrome
• Neuroendocrine Tumors
• Carcinoid Syndrome
• Other Treatments
• 6.3. Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Pharmaceutical Companies
• 6.4. Global Somatostatin Analogs Market, Sub-Segmentation Of Octreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Release (LAR) Formulations
• Short-Acting Formulations
• 6.5. Global Somatostatin Analogs Market, Sub-Segmentation Of Lanreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Depot Formulations
• Injectable Formulations
• 6.6. Global Somatostatin Analogs Market, Sub-Segmentation Of Pasireotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long-Acting Injectable Formulations
• Subcutaneous Formulations

7. Somatostatin Analogs Market Regional And Country Analysis

• 7.1. Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Somatostatin Analogs Market

• 8.1. Asia-Pacific Somatostatin Analogs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Somatostatin Analogs Market

• 9.1. China Somatostatin Analogs Market Overview
• 9.2. China Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Somatostatin Analogs Market

• 10.1. India Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Somatostatin Analogs Market

• 11.1. Japan Somatostatin Analogs Market Overview
• 11.2. Japan Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Somatostatin Analogs Market

• 12.1. Australia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Somatostatin Analogs Market

• 13.1. Indonesia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Somatostatin Analogs Market

• 14.1. South Korea Somatostatin Analogs Market Overview
• 14.2. South Korea Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Somatostatin Analogs Market

• 15.1. Western Europe Somatostatin Analogs Market Overview
• 15.2. Western Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Somatostatin Analogs Market

• 16.1. UK Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Somatostatin Analogs Market

• 17.1. Germany Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Somatostatin Analogs Market

• 18.1. France Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Somatostatin Analogs Market

• 19.1. Italy Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Somatostatin Analogs Market

• 20.1. Spain Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Somatostatin Analogs Market

• 21.1. Eastern Europe Somatostatin Analogs Market Overview
• 21.2. Eastern Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Somatostatin Analogs Market

• 22.1. Russia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Somatostatin Analogs Market

• 23.1. North America Somatostatin Analogs Market Overview
• 23.2. North America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Somatostatin Analogs Market

• 24.1. USA Somatostatin Analogs Market Overview
• 24.2. USA Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Somatostatin Analogs Market

• 25.1. Canada Somatostatin Analogs Market Overview
• 25.2. Canada Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Somatostatin Analogs Market

• 26.1. South America Somatostatin Analogs Market Overview
• 26.2. South America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Somatostatin Analogs Market

• 27.1. Brazil Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Somatostatin Analogs Market

• 28.1. Middle East Somatostatin Analogs Market Overview
• 28.2. Middle East Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Somatostatin Analogs Market

• 29.1. Africa Somatostatin Analogs Market Overview
• 29.2. Africa Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Somatostatin Analogs Market Competitive Landscape And Company Profiles

• 30.1. Somatostatin Analogs Market Competitive Landscape
• 30.2. Somatostatin Analogs Market Company Profiles
  • 30.2.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Midatech Pharma plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Crinetics Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Somatostatin Analogs Market Other Major And Innovative Companies

• 31.1. Peptron Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Camurus AB
• 31.4. Bayer Aktiengesellschaft
• 31.5. Cadila Healthcare Limited
• 31.6. Amneal Pharmaceuticals Inc.
• 31.7. Recordati S.p.A.
• 31.8. Amryt Pharma plc
• 31.9. Ipsen Pharma SA
• 31.10. Fresenius Kabi AG
• 31.11. Chiasma Inc.
• 31.12. Merck KGaA
• 31.13. Sanofi S.A.
• 31.14. Sandoz International GmbH
• 31.15. Takeda Pharmaceutical Company Limited

32. Global Somatostatin Analogs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Somatostatin Analogs Market

34. Recent Developments In The Somatostatin Analogs Market

35. Somatostatin Analogs Market High Potential Countries, Segments and Strategies

• 35.1 Somatostatin Analogs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Somatostatin Analogs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Somatostatin Analogs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer